SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report

Report for Clinical Trial NCT02770014

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Patient with Non-Small Cell Lung Cancer (NSCLC) that might have a genetic change (mutation) in the Epidermal Growth Factor Receptor (EGFR) are invited to take part in this study. This research study is evaluating a new blood test that is capable of detecting an EGFR mutation in cancer without a biopsy.

NCT02770014 Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer
MeSH: Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO: Neoplasm of the lung Non-small cell lung carcinoma

1 Interventions

Name: Erlotinib

Type: Drug

EGFR Exon 19 Positive Treatment With Erlotinib

Primary Outcomes

Measure: Overall Response Rate

Time: 2 years

Secondary Outcomes

Measure: - Determine The Time From Study Registration To Treatment Initiation Using A Rapid Plasma Genotyping Strategy Versus Standard Tumor Genotyping.

Time: 2 years

Measure: - Ascertain The Positive Predictive Value And False Negative Rate Of Plasma Genotyping For Patients With Recently Diagnosed Advanced NSCLC Among Patients With Tissue Available For Standard Genotyping

Time: 2 years
Purpose: Treatment

Single Group Assignment

There is one SNP

SNPs

1 L858R

Biopsy requirement may be waived if not technically feasible and plasma genotyping reveals an eligible EGFR mutation (exon 19 del/L858R). --- L858R ---


HPO Nodes

HPO:
Neoplasm of the lung
Genes 43
WT1 KRAS SLC22A18 STK11 IRF1 AKT1 C11ORF95 PRKN PPP2R1B ERBB2 TRPV3 TSC1 POU6F2 TSC2 EWSR1 RELA KEAP1 REST DIS3L2 SFTPA2 GPC3 MBTPS2 LMNA PTEN BRAF BRCA2 EGFR RB1 TRIP13 PDGFRB TERT SFTPC PIK3CA TRIM28 DICER1 MAP3K8 HPGD SLCO2A1 H19 TP53 NOTCH3 BAP1 WRN
Non-small cell lung carcinoma
Genes 2
TP53 BAP1